Hikma Pharmaceuticals plans $267 million Ohio expansion, adding 350 jobs

Hikma Pharmaceuticals is moving forward with a $267 million expansion across two Ohio manufacturing facilities, representing the regional execution of a $1 billion national investment strategy the London-based company outlined last year. The capital deployment aims to scale domestic production capacity amid growing U.S. demand for onshore drug manufacturing, giving Ohio another high-value anchor in its bid to become a top-tier biopharma hub.

Statewide expansion

The generic medication provider is splitting its infrastructure upgrades between two separate nodes of its Ohio footprint, targeting completely distinct product lines:

• Central Ohio ($216 Million): Hikma will scale its oral solid dose and nasal inhalation operations in Columbus, creating 50 jobs. The West Side facility already serves as one of Hikma's three global R&D hubs and stands as the largest manufacturing employer within the city of Columbus, according to the company and local officials.
• Northeast Ohio ($51 Million): In Bedford, the company will inject capital into its historic Northfield Road facility—a site utilized for pharmaceutical production since 1938—to create up to 300 jobs. This project will focus exclusively on sterile injectables, adding capabilities for advanced aseptic vial filling, IV bag production, and lyophilization (freeze-drying).

Between the lines

The expansion aligns with ongoing concerns around U.S. medical supply chain vulnerabilities. Hikma, which currently outputs more than 12 billion finished doses annually across its Ohio and New Jersey footprint, focuses heavily on the federal government's list of essential drugs. The company says it has worked closely with the FDA to resolve critical nationwide drug shortages by stepping up domestic production.

“Hikma’s expanded facilities in central and northeast Ohio will strengthen its ability to ensure patients have reliable access to the medicines they need,” said Governor Mike DeWine.

The Hikma playbook

Hikma's scale-up is positioned to lean heavily on Ohio's expanding specialized labor network. The company is slated to utilize a new biomanufacturing workforce training initiative launched by JobsOhio and the Ohio Life Sciences Association.

The program features a planned training facility in Columbus designed to anchor a "hub-and-spoke" academic network with state universities and technical schools. It builds on existing specialized paths, such as the cGMP (Current Good Manufacturing Practice) fundamentals training at Butler Tech and biotech bootcamps at Columbus State. The state currently ranks seventh nationally for biotech human capital, a metric Ohio economic development officials frequently cite to attract and anchor capital-intensive life sciences operations.

The advanced manufacturing pipeline

The investment adds to a growing pipeline of large-scale life sciences manufacturing projects expanding across the state. Hikma's multi-facility project lands alongside recent major expansions from players like Resilience in West Chester and AtriCure in Mason, signaling that Ohio is increasingly securing complex, automated biopharma production alongside its legacy heavy-manufacturing footprint.

The next steps

As is standard for economic development projects of this scale, the final deal mechanics are moving through the standard confirmation process for state and local incentives.

A coalition of partners—including JobsOhio, regional finance authorities, and the leadership of Columbus and Bedford—are working alongside Hikma to finalize the incentive packages, with specific construction milestones and hiring phases expected to unlock as those agreements conclude.

The Ohio Perspective

This dual-region investment underscores the growing interconnectedness of the Ohio Discovery Corridor—the life sciences corridor linking research hubs and production centers from Cleveland through Columbus down to Cincinnati. Hikma's decision to anchor its high-volume oral dose production in Central Ohio while centering its sterile injectables line in Northeast Ohio leverages the specific, localized manufacturing expertise inherent to each region.

"We are proud to continue building our Ohio workforce and our ability to make safe, affordable, high-quality medicines in Ohio for American patients," said Hafrun Fridriksdottir, President, Hikma US, and Chief R&D Officer.

JobsOhio President and CEO J.P. Nauseef added, "Hikma continues to serve as an example of why the future of medicine is being built in Ohio."

The macro view

Beyond regional job creation, the expansion cements Ohio's structural role in resolving a critical national problem: the vulnerability of the essential medicine supply chain. By scaling up advanced production lines on American soil, Hikma is betting that Ohio’s combination of logistical positioning, industrial workforce heritage, and targeted educational initiatives makes it the most stable environment for long-term pharmaceutical manufacturing.

Instead of routing advanced biopharma projects exclusively to legacy coastal tech hubs, the capital allocation confirms that the operational infrastructure required to de-risk the nation's drug supply is effectively being scaled in the Midwest.